Lukas Biomedical Inc. (6814.TWO)
- Previous Close
23.50 - Open
23.50 - Bid 22.90 x --
- Ask 23.30 x --
- Day's Range
23.00 - 23.75 - 52 Week Range
16.60 - 37.35 - Volume
17,395 - Avg. Volume
21,726 - Market Cap (intraday)
981.046M - Beta (5Y Monthly) 0.04
- PE Ratio (TTM)
-- - EPS (TTM)
-2.38 - Earnings Date --
- Forward Dividend & Yield --
- Ex-Dividend Date --
- 1y Target Est
--
Lukas Biomedical Inc. engages in the wholesale and retail of cosmetics in Taiwan. It operates through E-Commerce, Medical Management Business, Cell Products, and Pharmaceutical Market Development segments. The company also researches and develops immune cell medical technology for regenerative medicine and adjuvant treatment; engages in clinical trials; distributes immune cell therapy culture technology; and leases housing equipment. In addition, the company offers cell reagents; and brand management and consulting services. Lukas Biomedical Inc. was founded in 2002 and is based in New Taipei City, Taiwan.
lukas-bio.com.twRecent News: 6814.TWO
View MorePerformance Overview: 6814.TWO
Trailing total returns as of 6/13/2025, which may include dividends or other distributions. Benchmark is TSEC CAPITALIZATION WEIGHTED ST (^TWII) .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: 6814.TWO
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: 6814.TWO
View MoreValuation Measures
Market Cap
981.05M
Enterprise Value
1.03B
Trailing P/E
--
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
4.87
Price/Book (mrq)
3.01
Enterprise Value/Revenue
5.43
Enterprise Value/EBITDA
--
Financial Highlights
Profitability and Income Statement
Profit Margin
-49.72%
Return on Assets (ttm)
-12.55%
Return on Equity (ttm)
-31.15%
Revenue (ttm)
189.83M
Net Income Avi to Common (ttm)
-94.38M
Diluted EPS (ttm)
-2.38
Balance Sheet and Cash Flow
Total Cash (mrq)
64.71M
Total Debt/Equity (mrq)
35.36%
Levered Free Cash Flow (ttm)
-41.56M